Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies

CNS Neuroscience and Therapeutics

Volumn 22, Issue 3, 2016, Pages 159-166

  Cummings, Jeffrey ^a   Lai, Te Jen ^b   Hemrungrojn, Solaphat ^c   Mohandas, E ^d   Yun Kim, Sang ^e   Nair, Girish ^f   Dash, Amitabh ^g  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Sun Medical and Research Centre ^*  (India)

^e Seoul National University Bundang Hospital   (South Korea)

^f Department of Neurology   (India)

^g EISAI CO LTD   (Japan)

Author keywords

Alzheimer disease; Behavioral symptoms; Cholinesterase inhibitors; Dementia; Donepezil

Indexed keywords

ANTIDEPRESSANT AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; RIVASTIGMINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGGRESSION; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; COGNITIVE DEFECT; COGNITIVE THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DELUSION; DEPRESSION; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENERAL MENTAL DISEASE ASSESSMENT; HALLUCINATION; HEALTH CARE COST; HUMAN; IRRITABILITY; MENTAL DISEASE; META ANALYSIS (TOPIC); NEUROPSYCHIATRIC INVENTORY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOEDUCATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; VISUAL HALLUCINATION; COMPLICATION; PSYCHOTIC DISORDERS;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; LEWY BODY DISEASE; PIPERIDINES; PSYCHOTIC DISORDERS;

EID: 84958653537     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12484     Document Type: Article

References (54)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
2. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-850.
3. Winblad B, Black SE, Homma A. Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials. Curr Med Res Opin 2009;25:2577-2587.
4. Lawlor B. Managing behavioural and psychological symptoms in dementia. Br J Psychiatry 2002;181:463-465.
5. Tampi RR, Williamson D, Muralee S, et al. Behavioral and psychological symptoms of dementia: Part I-epidemiology, neurobiology, heritability, and evaluation. Clin Geriatr 2011;19:1-6.
6. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-361.
7. Lai MK, Lai OF, Keene J, et al. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 2001;57:805-811.
8. Pinto T, Krista L, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev 2011;10:404-412.
9. Cummings JL. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11(Suppl 4):S1-S9.
10. Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioral and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 2006;127:158-165.
11. Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010;59:221-229.
12. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 2003;49:55-60.
13. Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 1997;48(Suppl 6):S10-S16.
14. World Health Organization. Neurological disorders: Public health challenges. Chapter 3: A public health approach. Geneva: World Health Organization; 2006. Available from: www.who.int/mental_health/neurology/neurodiso/en/ Accessed 22 January 2015.
15. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry 1987;48(Suppl):9-15.
16. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989;44:M77-M84.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
18. Fernández M, Gobartt AL, Balañá M, et al. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 2010;10:87.
19. Tampi RR, Williamson D, Muralee S, et al. Behavioral and psychological symptoms of dementia: Part II-treatment. Clin Geriatr 2011;19:2-10.
20. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005;293:596-608.
21. Donnelly ML. Behavioral and psychological disturbances in Alzheimer disease: Assessment and treatment. B C Med J 2005;47:487-493.
22. Bergman J, Brettholz I, Shneidman M, Lerner V. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clin Neuropharmacol 2003;26:88-92.
23. Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatry 2011;168:831-839.
24. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008;165:844-854.
25. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.
26. US Food and Drug Administration. Public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171 Accessed 22 January 2015.
27. Carrasco MM, Agüera L, Gil P, Moríñigo A, Leon T, on behalf of the PSyAL Study Group. Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25: 333-340.
28. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
29. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002; 18: 347-354.
30. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25:313-317.
31. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
32. Cummings JL, McRae T, Zhang R. The Donepezil-Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-611.
33. Mega MS, Dinov ID, Lee L, et al. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:209-218.
34. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219.
35. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
36. Feldman H, Gauthier S, Hecker J, et al., and the Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005;20:559-569.
37. Campbell N, Ayub A, Boustani MA, et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis. Clin Interv Aging 2008;3:719-728.
38. Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 2014;41:615-631.
39. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis 2013;35:349-361.
40. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 2008;3:211-225.
41. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
42. Winblad B, Kilander L, Eriksson S, et al.; for the Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065.
43. Rogers SL. Perspectives in the management of Alzheimer's disease: Clinical profile of donepezil. Dement Geriatr Cogn Disord 1998;9(Suppl 3):29-42.
44. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: Drug profile and clinical guidelines. CNS Neurosci Ther 2013;19:294-301.
45. Thompson S, Lanctôt KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004;3:425-440.
46. Mori E, Ikeda M, Kosaka K; on behalf of the Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.
47. ® approved in Japan as treatment for dementia with Lewy bodies. World's first treatment for both Alzheimer's disease and dementia with Lewy bodies. News release: 19 September 2014. Available from: http://www.eisai.com/news/news201452.html Accessed 12 May 2015.
48. Ikeda M, Mori E, Kosaka K, et al.; on behalf of the Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: Results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013;36:229-241.
49. Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015;7:4.
50. Ukai K, Fujishiro H, Iritani S, Ozaki N. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics 2015;15:133-137.
51. Manabe Y, Ino T, Yamanaka K, Kosaka K. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Psychogeriatrics 2015. doi: 10.1111/psyg.12140 [Epub ahead of print].
52. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17:403-408.
53. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721-1729.
54. Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. BMC Neurol 2012;12:2.